Zoetis price target raised to $213 from $204 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Zoetis to $213 from $204 and keeps a Buy rating on the shares after its Q2 earnings beat. The analyst cites the company’s improved performance and notes that despite some areas of softness, its Librela growth is “encouraging”. Goldman Sachs adds it is more positive on the outlook for pain mAb growth post the quarter.